NewGenIvf Completes Third Debt Financing Tranche
Ticker: NIVFW · Form: 6-K · Filed: Nov 15, 2024 · CIK: 1981662
| Field | Detail |
|---|---|
| Company | Newgenivf Group LTD (NIVFW) |
| Form Type | 6-K |
| Filed Date | Nov 15, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $1,500,000, $1,395,000, $0.658 |
| Sentiment | neutral |
Sentiment: neutral
Topics: debt-financing, financing-update, sec-filing
TL;DR
NewGenIvf just closed another debt financing round, signaling ongoing capital access.
AI Summary
NewGenIvf Group Limited announced on November 11, 2024, the completion of the third tranche of its debt financing. This follows the terms of a Securities Purchase Agreement previously filed with the SEC.
Why It Matters
This financing event indicates continued access to capital for NewGenIvf, which is crucial for its operational and growth strategies.
Risk Assessment
Risk Level: medium — Debt financing can introduce financial leverage and repayment obligations, which carry inherent risks.
Key Players & Entities
- NewGenIvf Group Limited (company) — The company filing the report and completing the financing.
- November 11, 2024 (date) — Date of the consummation of the third tranche of debt financing.
- Securities Purchase Agreement (document) — The agreement governing the debt financing.
FAQ
What is the total amount of debt financing secured in this third tranche?
The filing does not specify the dollar amount for the third tranche of debt financing.
When was the Securities Purchase Agreement initially entered into?
The filing references a previous Form 6-K for the Securities Purchase Agreement but does not state the initial entry date within this document.
What are the terms of the debt financing mentioned in the Securities Purchase Agreement?
The specific terms of the debt financing are not detailed in this Form 6-K, which refers to a previously filed document for the agreement.
Has NewGenIvf Group Limited filed its annual report on Form 20-F?
The registrant indicates it files or will file annual reports under cover of Form 20-F, with a checkmark next to it.
What is the principal executive office address of NewGenIvf Group Limited?
The principal executive offices are located at 36/39-36/40, 13th Floor, PS Tower Sukhumvit 21 Road (Asoke) Khlong Toei Nuea Sub-district Watthana District, Bangkok 10110 Thailand.
Filing Stats: 515 words · 2 min read · ~2 pages · Grade level 12.9 · Accepted 2024-11-15 15:05:39
Key Financial Figures
- $1,500,000 — Note”) in the principal amount of $1,500,000, after the effective date of the Regist
- $1,395,000 — d Additional Mandatory Note resulted in $1,395,000 of gross proceeds to the company before
- $0.658 — quo;) at an initial conversion price of $0.658. No fractional Class A Shares are issua
Filing Documents
- ea0221458-6k_newgen.htm (6-K) — 13KB
- ea022145801ex4-1_newgen.htm (EX-4.1) — 286KB
- 0001213900-24-099047.txt ( ) — 301KB
From the Filing
OF FOREIGN PRIVATE ISSUER UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission file number: 001-42004 NEWGENIVF GROUP LIMITED 36/39-36/40, 13th Floor, PS Tower Sukhumvit 21 Road (Asoke) Khlong Toei Nuea Sub-district Watthana District, Bangkok 10110 Thailand (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20- F Form 40-F EXPLANATORY NOTE On November 11, 2024, NewGenIvf Group Limited (“Company”) consummated the third tranche of its debt financing under the terms of the Securities Purchase Agreement (“SPA”) referenced in the current report on Form 6-K filed with the United States Securities and Exchange Commission (the “SEC”) on August 16, 2024. The Form 6-K filed with the SEC on August 16, 2024 is incorporated by reference herein. Pursuant to the terms of the SPA, the Company may elect at the second additional mandatory closing to sell and the institutional investor party to the SPA shall be required to purchases, subject to certain conditions, an additional note (“Second Additional Mandatory Note”) in the principal amount of $1,500,000, after the effective date of the Registration Statement (as defined in the SPA). The sale of the Second Additional Mandatory Note resulted in $1,395,000 of gross proceeds to the company before fees and expenses. Like the prior notes, the Second Additional Mandatory Note bears an interest rate of 14.75% per annum and may be adjustable from time to time pursuant to its terms. The Second Additional Mandatory Note will mature on the four years and six month anniversary of the date of issuance, subject to extension at the option of the holders in certain circumstances as provided in such note. All amounts due under the Second Additional Note are convertible at any time, in whole or in part, into validly issued, fully paid and non-assessable Class A Ordinary Shares (“Class A Shares”) at an initial conversion price of $0.658. No fractional Class A Shares are issuable upon any such conversion. If the issuance would result in the issuance of a fraction of a Class A Share, the Company shall round such fraction of a Class A Share up to the nearest whole share. The form of the Second Additional Mandatory Note is filed as Exhibit 4.1 hereto. The foregoing is only a brief description of the Second Additional Mandatory Note and such description is qualified in its entirety by reference to the full text of the Note, filed as Exhibit 4.1 in this current report on Form 6-K. 1 EXHIBITS Exhibit No. Description 4.1 Form of Note 2 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NewGenIvf Group Limited By: /s/ Wing Fung Alfred Siu Name: Wing Fung Alfred Siu Title: Chairman of the Board and Director Date: November 15, 2024 3